Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Soligenix is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201), and its novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.
BioDefense and Emerging Diseases
Soligenix BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate, OrbeShield®, its GI acute radiation syndrome therapeutic candidate and SGX101 and SGX943, its melioidosis therapeutic candidates. The development of the vaccine programs incorporates the use of a proprietary heat stabilization platform technology, known as ThermoVax®. Currently, this business segment is supported with up to $57 million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).